Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts

David Lyden, Alison Z. Young, David Zagzag, Wei Yan, William Gerald, Richard O'Reilly, Bernhard L. Bader, Richard O. Hynes, Yuan Zhuang, Katia Manova and Robert Benezra ()
Additional contact information
David Lyden: Memorial Sloan-Kettering Cancer Center
Alison Z. Young: Memorial Sloan-Kettering Cancer Center
David Zagzag: Kaplan Cancer Center
Wei Yan: Memorial Sloan-Kettering Cancer Center
William Gerald: Memorial Sloan-Kettering Cancer Center
Richard O'Reilly: Memorial Sloan-Kettering Cancer Center
Bernhard L. Bader: Max-Planck-Institute for Biochemistry
Richard O. Hynes: Massachusetts Institute of Technology
Yuan Zhuang: Duke University Medical Center
Katia Manova: Memorial Sloan-Kettering Cancer Center
Robert Benezra: Memorial Sloan-Kettering Cancer Center

Nature, 1999, vol. 401, issue 6754, 670-677

Abstract: Abstract Id proteins may control cell differentiation by interfering with DNA binding of transcription factors. Here we show that targeted disruption of the dominant negative helix–loop–helix proteins Id1 and Id3 in mice results in premature withdrawal of neuroblasts from the cell cycle and expression of neural-specific differentiation markers. The Id1–Id3 double knockout mice also display vascular malformations in the forebrain and an absence of branching and sprouting of blood vessels into the neuroectoderm. As angiogenesis both in the brain and in tumours requires invasion of avascular tissue by endothelial cells, we examined the Id knockout mice for their ability to support the growth of tumour xenografts. Three different tumours failed to grow and/or metastasize in Id1+/-Id3-/- mice, and any tumour growth present showed poor vascularization and extensive necrosis. Thus, the Id genes are required to maintain the timing of neuronal differentiation in the embryo and invasiveness of the vasculature. Because the Id genes are expressed at very low levels in adults, they make attractive new targets for anti-angiogenic drug design.

Date: 1999
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/44334 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:401:y:1999:i:6754:d:10.1038_44334

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/44334

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().